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A B S T R A C T
Background and purpose: Magnetic Resonance (MR)-Only radiotherapy requires a method for matching image
with on-treatment Cone Beam Computed Tomography (CBCT). This study aimed to investigate the accuracy of
MR-CBCT soft-tissue matching for prostate MR-only radiotherapy.
Materials and methods: Three patient cohorts were used, with all patients receiving MR and CT scans. For the first
cohort (10 patients) the first fraction CBCT was automatically rigidly registered to the CT and MR scans and the
MR-CT registration predicted using the MR-CBCT and CT-CBCT registrations. This was compared to the auto-
matic MR-CT registration. For the second and third cohorts (five patients each) the first fraction CBCT was
independently matched to the CT and MR by four radiographers, the MR-CBCT and CT-CBCT matches compared
and the inter-observer variability assessed. The second cohort used a CT-based structure set and the third a MR-
based structure set with the MR relabelled as a ‘CT’.
Results: The mean difference between predicted and actual MR-CT registrations was = ±R 0.1 0.2 mmAll
(s.e.m.). Radiographer MR-CBCT registrations were not significantly different to CT-CBCT, with mean differ-
ences in soft-tissue match 0.2 mm and all except one difference . This was less than the MR-CBCT inter-
observer limits of agreement [3.5, 2.4, 0.9] mm (vertical, longitudinal, lateral), which were similar ( 0.5 mm) to
CT-CBCT.
Conclusions: MR-CBCT soft-tissue matching is not significantly different to CT-CBCT. Relabelling the MR as a
‘CT’ does not appear to change the automatic registration. This suggests that MR-CBCT soft-tissue matching is
feasible and accurate.
1. Introduction
Magnetic Resonance (MR)-Only radiotherapy enables the superior
soft-tissue contrast of MR [1] to be used for organ delineation without
the uncertainties of a MR-Computed Tomography (CT) registration [2].
MR-only radiotherapy requires a method of generating a synthetic CT
(sCT) from the MR that can be used for radiotherapy dose calculations
[3]. Commercial solutions with high dosimetric accuracy are now being
used clinically in the treatment of prostate cancer [4,5].
In a MR-CT fusion workflow the CT is not just used for organ deli-
neation and treatment planning but also as the reference image for on-
treatment image matching, typically using kilovoltage planar or Cone
Beam CT (CBCT) images [6]. So far, clinical implementations of MR-
only radiotherapy for prostate cancer have used implanted fiducial
markers for image guidance with the markers digitally added to the sCT
[7,4,5]. However a significant number of centres do not use fiducial
markers and employ CBCT soft-tissue matching for prostate radio-
therapy treatments (~60% of UK centres) [8]. Additionally, radiotherapy
treatments of many other cancers are not conventionally performed
with implanted fiducial markers. Therefore for MR-only radiotherapy to
be used more broadly, it is essential that methods of on-treatment
imaging matching to CBCT are developed.
Several studies have reported using sCTs as the reference image for
CBCT matching for prostate cancer. Korhonen et al. reported mean
differences in CT-CBCT and sCT-CBCT matches as 0.3 mm in all di-
rections [9]. Chen et al. found translational vector differences between
CT-CBCT and sCT-CBCT automatic matches 1.08 mm and rotational
differences °1.1 for all three axes [10]. However the sCT soft-tissue
image quality is often poor, which does not affect the dosimetric ac-
curacy but would be detrimental for CBCT soft-tissue matching. This
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suggests that the optimum reference image in a MR-only pathway
would be the MR itself.
Two studies have investigated MR-CBCT matching for prostate MR-
only radiotherapy [9,11]. Korhonen et al. found small ( 1.5 mm) mean
differences in each direction between automatic MR-CBCT and CT-
CBCT registrations [9]. This did not assess the manual adjustments
routinely performed by treatment radiographers in a soft-tissue match
and so did not investigate the accuracy of the clinical process. Doemer
et al. similarly found mean differences between manual MR-CBCT and
CT-CBCT registrations to be 1.5 mm in each direction [11]. However,
both studies only used a single observer and so were unable to compare
the match differences with the inter-observer variability. In addition,
both studies only used data from patients treated with a CT-based plan
and contours, which may have affected the results. This study aimed to
assess the accuracy of MR-CBCT soft-tissue matching for prostate MR-
only radiotherapy using the clinical process with multiple observers
using patient data from both CT-based and MR-based plans and con-
tours.
2. Materials and methods
2.1. Patient data collection
This was a retrospective study including 20 patients treated with
radiotherapy for prostate cancer at the Northern Centre for Cancer
Care, Newcastle upon Tyne, UK. The patients were divided into three
cohorts: registration commutation assessment (one), CT-based plan
radiographer assessment (two) and MR-based plan radiographer as-
sessment (three). Cohorts one (10 patients) and two (five patients) were
selected retrospectively from all patients treated with radical radio-
therapy for prostate cancer using a CT-based plan between 5 March and
3 April 2018. The following exclusion criteria were applied (number of
patients excluded): MR not acquired (5), kilovoltage CBCT not acquired
(4), patient external contour larger than MR field of view (1). Cohort
three consisted of the first five patients treated using a novel MR-only
radiotherapy pathway. The cohorts were similar, with median ages of
75, 72 and 71 years for cohorts one, two and three respectively.
All patients received planning MR (1.5 T Magnetom Espree,
Siemens, Erlangen, Germany) and, the following day, CT (Sensation
Open, Siemens) scans, performed on flat couch tops with local standard
immobilisation. Prior to each scan patients underwent routine bladder
and bowel preparation, consisting of a micro-enema application 60 min
prior to the scan followed by bowel and bladder emptying 30 min later,
then drinking 400 ml of water. Internal fiducial markers were not pre-
sent. The MR images were acquired using a 6 channel flexible Body
Matrix coil supported over the patient by an in–house manufactured
coil bridge and the 24 channel Spine Matrix coil contained in the couch.
A SPACE (Sampling Perfection with Application optimised Contrasts
using different flip angle Evolution) 3D turbo spin echo sequence was
used, with a field of view of × ×450 450 180 mm3 with a voxel size× ×1.4 1.4 1.5 mm3. A bandwidth of 601 HzPixel 1 and the Siemens 3D
distortion correction algorithm was used to minimise geometric dis-
tortion [12]. This was previously measured using a GRADE phantom
(Spectronic Medical, Helsingborg, Sweden) [13], with maximum dis-
tortion =D 2.5 mmmax and 99 % of phantom markers having distortion<D 2.0 mm. The images were T2-weighted with echo time=TE 211 ms, repetition time =TR 1500 ms, flip angle = °150 and
acquisition time =T 281 s. For cohort three this MR image was used to
create the sCT for dose calculations using MriPlanner (Spectronic). The
CT images were acquired with a voxel size of × ×1.1 1.1 3 mm3 and a
tube voltage of =V 120 kVp.
All patients were treated with 60 Gy in 20 fractions [14] with daily
kilovoltage CBCT imaging using a TrueBeam STx (version 2.7 MR3,
Varian Medical Systems, Palo Alto, USA). CBCT images were acquired
with a voxel size of × ×0.9 0.9 2 mm3, field of view 46.5 cm and tube
voltage =V 125 kVp.
2.2. Registration commutation assessment
The first fraction CBCT for patient cohort one was registered to the
CT and to the MR using the automatic mutual information algorithm
within RayStation (version 7, RaySearch Laboratories, Stockholm,
Sweden). The registration used was a rigid registration with three de-
grees of freedom (translations only). The MR-CBCT and CT-CBCT re-
gistrations were then subtracted to predict a MR-CT registration using
=R R R ,CTMR CBCTMR CBCTCT (1)
where RBA is the measured registration matrix registering the floating
image A to the reference image B and RBA is the predicted registration
matrix between images A and B.
A rigid registration with three degrees of freedom between the MR
and the CT was also calculated using the same methodology (RCTMR). This
measured registration matrix was compared to the predicted registra-
tion matrix from Eq. (1) using =R R RCTMR CTMR CTMR.
2.3. Radiographer matching assessment
Cohort two was used for the CT-based plan radiographer assess-
ment. Each patient MR was automatically registered to the CT in
RayStation focused on the Planning Target Volume (PTV), with 6 de-
grees of freedom (translations and rotations). The CT-based contours
were transferred to the MR using this registration matrix. For cohort
two the contours were a prostate-only Gross Tumour Volume (GTV) and
prostate and seminal vesicles volume (GTV1), with three expansions
used to create three PTVs [14]. The GTV and GTV1 were contoured on a
separate small field of view MR scan acquired in the same session as the
MR described in the methods and copied onto the CT. If there were
discrepancies in soft-tissue anatomy between MR and CT (eg bladder
filling) the GTV was then modified using the CT. The organs at risk
(bladder and the rectum) were contoured directly on the CT. The first
fraction CBCT was matched independently to the CT and to the MR
using Aria (version 13.6, Varian) by four senior treatment radio-
graphers with at least 3 years experience in prostate CT-CBCT
matching. Each radiographer received additional training in MR prior
to this study, consisting of MR pelvic anatomy outlining with a urology
Consultant Clinical Oncologist, offline MR-CBCT matching experience
followed by offline MR-CBCT matching benchmarking (see Fig. 1 for an
example).
Two matches were carried out for each image set: an automatic
match and a manual adjustment match based on soft-tissue information
in the CBCT and the clinical delineations on the reference image (CT or
MR). Both matches were translations only (three degrees of freedom).
The starting point for each match was the centre of the CBCT image
aligned to the treatment isocentre in the middle of the PTV. The centre
of the CBCT image was the initial set-up to the treatment isocentre. The
automatic registration algorithm within Aria is mutual information
based and is the algorithm used by the TrueBeam during online treat-
ment image matching.
The accuracy of MR-CBCT matching was assessed by using the CT-
CBCT match as a gold standard and calculating the difference between
each radiographer’s MR-CBCT match and CT-CBCT match. The mean
difference was assessed in each direction (vertical,longitudinal,lateral)
and over all directions.
The MR-only plan assessment (cohort three) used the reverse pro-
cess to cohort two, with the CT rigidly registered to the MR and the MR
contours transferred to the CT. The contours were the same as cohort
two but with the bladder and rectum contoured directly on the MR. In
order for the MR to be used for online image guidance the MR was
relabelled as a ‘CT’ since the current clinical versions of Aria and the
TrueBeam will only accept a CT as the primary reference image. This
involved changing the DICOM tags Modality, SOPClassUID and
RescaleType to ‘CT’, ‘1.2.840.10008.5.1.4.1.1.2’ and ‘HU’ respectively.
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In addition, Aria will only accept non-CT additional reference data sets
and so the CT was relabelled as an ‘MR’ by changing the DICOM tags
Modality, SOPClassUID, ScanningSequence and SequenceVariant to
‘MR’, ‘1.2.840.10008.5.1.4.1.1.4’, ‘RM’ and ‘NONE’ respectively. The
same four radiographers independently matched the first fraction CBCT
to the MR and to the CT as for cohort two.
The inter-observer variability of MR-CBCT and CT-CBCT soft-tissue
matching was assessed with combined data from cohorts two and three.
It was measured using an extension of the Bland-Altman method for
multiple observers [15]. The difference between each observer’s match
and the mean of all observers match was plotted as a function of the
mean of all observers match. Limits of Agreement (LoA) were estimated
using the methodology detailed in Ref. [15] and give an assessment of
the disagreement of the observers with the mean of all observers. The
inter-observer error was also calculated as the standard deviation of the
shifts across all four observers for each patient [16].
3. Results
3.1. Commutation assessment (Cohort One)
The differences between predicted and actual registration matrix
are shown in Fig. 2. The mean difference in the vertical direction was= ±R 0.7 0.4 ( 3.2, 1.4) mmVert (± standard error of the mean
(minimum, maximum)). The mean differences in the longitudinal and
lateral directions were smaller, = ±R 0.3 0.1 ( 0.6, 0.8)Long and= ±R 0.1 0.1 ( 0.6, 0.6)Lat , and across all directions was= ±R 0.1 0.2 mmAll .
3.2. Radiographer matching assessment (Cohorts Two and Three)
The mean difference in MR-CBCT and CT-CBCT automatic match
was 0.7 mm over all directions and for the soft-tissue match 0.2 mm
(see Table 1). All the soft-tissue match differences were within± 3.3 mm except for one outlier in the longitudinal direction (see
Fig. 3). The CT plan and MR-only plan cohorts had similar spread of
Fig. 1. Example MR-CBCT match in Aria with the PTV (red), bladder (yellow) and rectum (brown) planning structures shown. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 2. Box plot of differences between predicted and actual MR-CT registration
for the commutation assessment (patient cohort 1). There does appear to be a
larger spread and a systematic offset in the vertical direction compared to the
other two.
Table 1
The mean ± standard error of the mean (minimum, maximum) difference be-
tween MR-CBCT and CT-CBCT match (MR – CT). Cohort two patients were
planned and treated using CT and matched with images correctly labelled.
Cohort three patients were planned and treated using MR-only and matched
with images which were DICOM relabelled (MR to ‘CT’ and CT to‘MR’) to en-
able the MR to be the primary reference image.
Match Type Axis Mean MR-CBCT and CT-CBCT Difference/mm
Cohort Two Cohort Three
Automatic Vertical ±0.2 0.2 ( 1.7, 1.5) ±0.6 0.3 ( 2.6, 1.8)
Longitudinal ±0.5 0.2 ( 2.7, 1.0) ±0.7 0.3 ( 1.4, 2.4)
Lateral ±0.1 0.2 ( 1.7, 1.2) ±0.3 0.2 ( 1.4, 1.0)
All ±0.3 0.1 ( 2.7, 1.5) ±0.1 0.2 ( 2.6, 2.4)
Soft-Tissue Vertical ±0.1 0.3 ( 2.7, 1.8) ±0.1 0.3 ( 3.3, 3.0)
Longitudinal ±0.2 0.3 ( 2.2, 1.9) ±0.2 0.5 ( 7.9, 2.4)
Lateral ±0.1 0.2 ( 1.7, 1.2) ±0.1 0.2 ( 1.6, 1.0)
All ±0.1 0.1 ( 2.7, 1.9) ±0.1 0.2 ( 7.9, 3.0)
J.J. Wyatt, et al. Physics and Imaging in Radiation Oncology 12 (2019) 49–55
51
MR-CBCT and CT-CBCT differences in the automatic match.
There appeared to be more inter-observer variability (Fig. 4) in the
vertical direction for both CT-CBCT and MR-CBCT soft-tissue matches,
with LoA being 3.0 mm and 3.5 mm for CT-CBCT and MR-CBCT matches
respectively. In the other two directions the inter-observer variability
was smaller, with the respective CT-CBCT and MR-CBCT LoA being
1.9 mm and 2.4 mm for the longitudinal direction and 0.5 mm and
0.9 mm for the lateral. The automatic matches showed similar inter-
observer variability in all three directions, [0.9, 1.1, 0.6] mm (verti-
cal,longitudinal, lateral) for the CT-CBCT matches and [1.4, 1.4, 0.9] mm
for the MR-CBCT matches. There was 0.5 mm difference between the
CT-CBCT and MR-CBCT LoA in any direction in either the automatic or
Fig. 3. Box plots of the difference between MR-CBCT and CT-CBCT (MR-CT) automatic (top) and soft-tissue (bottom) matches. CT-based plan patients (cohort two)
are shown in blue and MR-only plan patients (cohort three) in red. (For interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
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Fig. 4. The modified Bland-Altman plots showing the difference in match for each observer compared to the mean of all observers as a function of the mean of all
observers. The blue, red, green and yellow circles indicate radiographers one, two, three and four respectively. The dashed lines show the Limits of Agreement (LoA).
The CT-CBCT inter-observer variability is shown on the left-hand plots and the MR-CBCT variability on the right-hand plots for the vertical (top), longitudinal
(middle) and lateral (bottom) directions. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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soft-tissue matches. The inter-observer error (Table 2) displayed similar
results, with the vertical direction showing more variability for both
MR-CBCT and CT-CBCT soft-tissue matches and the automatic matches
being similarly variable in all directions. Again there was very little
difference ( 0.4 mm) between the inter-observer error for MR-CBCT
and CT-CBCT.
4. Discussion
This study has evaluated the accuracy of CBCT soft-tissue matching
using an MR as the reference image for MR-only prostate radiotherapy.
The differences between MR-CBCT and CT-CBCT matching were small,
with the mean differences for both automatic and soft-tissue matching
being 0.7 mm in all directions. The mean soft-tissue matching dif-
ference was 0.2 mm, which is substantially less than the CT-CBCT
soft-tissue matching inter-observer variability reported in this study of
[3.0, 1.9, 0.5] mm (vertical, longitudinal, lateral). All except one differ-
ence in soft-tissue match was 3.3 mm. The patient with a larger dif-
ference had substantially different rectal filling in the CBCT compared
to the MR despite undergoing identical bowel preparation, which may
explain this outlier result. This suggests that MR-CBCT soft-tissue
matching is as accurate as CT-CBCT soft-tissue matching for prostate
radiotherapy.
Currently both Elekta and Varian linear accelerator manufacturers
require the primary reference image, which is the only image available
for on-line image matching, to be a CT. Therefore to be able to imple-
ment MR-CBCT matching as part of a MR-only radiotherapy process, it
is necessary to relabel the MR as a DICOM ‘CT’. This appeared to have
no impact on the performance of the automatic image registration al-
gorithm in Aria, with the distribution of the differences being similar
between cohorts two and three (see Fig. 3). There appeared to be a
slight difference in the longitudinal direction (cohort two 0.5 mm
versus cohort three 0.7 mm), however the mean differences still agreed
within the longitudinal inter-observer variability for the automatic CT-
CBCT matches (LoA 1.1 mm), suggesting that this was not clinically
significant.
This study has assessed the accuracy of MR-CBCT matching by using
the CT-CBCT match as the gold standard. This was reasonable as CT-
CBCT matching is the current clinical standard but it does have some
potential limitations. The first issue is that differences in MR-CBCT and
CT-CBCT match for the same patient depend on the quality of the MR-
CT registration. If the internal anatomy was substantially different be-
tween the MR and CT (eg large differences in bladder filling), this could
have resulted in a sub-optimal MR-CT registration and therefore a dif-
ference in the CT-CBCT and MR-CBCT matches, causing an over-esti-
mation of the MR-CBCT uncertainty for that patient. Over a patient
population the MR-CT registration errors will tend to push the mean
difference in MR-CBCT and CT-CBCT matches to zero but broaden the
standard deviation of these differences. This issue was attempted to be
controlled for by focusing the MR-CT registration on the prostate-only
PTV, since the prostate position is relatively insensitive to differences in
bladder filling [17]. In this study the very small standard errors of the
mean ( 0.5 mm) suggest that MR-CT registration errors did not cause
an under-estimation of the MR-CBCT uncertainty.
The second related issue is the structure set used by the radio-
graphers in assessing the soft-tissue match. In order to ensure an ac-
curate comparison between the MR-CBCT and CT-CBCT match, the
same structure set was used for both matches (CT-based structures for
cohort two and MR-based structures for cohort three). Again, if there
were differences in the internal anatomy between the MR and the CT,
this would have resulted in a discrepancy on one of the images between
the reference image data and the outlined structure. This was controlled
by using two cohorts, one with CT-based structures and the other with
MR-based structures to assess if there was a systematic difference be-
tween the two. The common structure set may explain why the mean
differences in soft-tissue matches (where the radiographers used the
structures) were smaller than the automatic matches.
The final issue is the poorer soft-tissue contrast of CT compared to
MR. A priori this would suggest that radiographers would find soft-
tissue matching using MR easier and more accurate than with CT, and
therefore differences between MR-CBCT and CT-CBCT matches may be
due to the MR-CBCT match being closer to the ground truth [9]. This
issue is very hard to control for and is a limitation of this study.
However, the small mean differences indicate that MR-CBCT soft-tissue
matching is at least as accurate as CT-CBCT.
The results in this study compare well with the two other studies
investigating MR-CBCT matching. Doemer et al. used a manual MR-
CBCT registration which was compared to the clinical CT-CBCT regis-
tration and found mean differences of
[ ± ± ±1.5 2.5, 0.7 1.9, 0.1 1.4]mm (vertical,longitudinal,lateral)
[11]. Korhonen et al. used an automatic registration focused on a 10 cm
cube in the centre of the images [9]. They reported mean differences to
CT-CBCT match of [ ± ± ±1.5 0.6, 0.7 0.7, 0.5 1.2]mm (vertical,longi-
tudinal,lateral). The mean differences found in this study were similar
in the longitudinal and lateral directions and smaller in the vertical
direction (see Table 1). This corroborates the finding of this study that
MR-CBCT soft-tissue matching is not significantly different to CT-CBCT
matching.
The inter-observer variability was very similar between CT-CBCT
and MR-CBCT registrations, with LoA and inter-observer errors being
within 0.5 mm for each direction. The vertical direction showed more
inter-observer variability for the soft-tissue matches than the other di-
rections, which was true for both CT-CBCT and MR-CBCT matches (see
Fig. 4). Manual soft-tissue matching involves balancing the coverage of
the prostate and the seminal vesicles. If the seminal vesicles on the
CBCT are shifted compared to the reference image, this balance will
involve clinical judgement which is likely to increase inter-observer
variability, primarily in the vertical direction. To authors’ knowledge,
MR-CBCT inter-observer variability for prostate matching has not been
reported previously in the literature. McNair et al. investigated the
inter-observer variability of CT-CBCT soft-tissue matching and reported
mean inter-observer error of ± ±1.6 0.7 mm, 1.4 0.9 mm and±0.4 0.3 mm (± standard deviation) for the vertical, longitudinal and
lateral directions repectively [16]. This agrees well with the results
found in this study with both the CT-CBCT and MR-CBCT inter-observer
errors being lower but within one standard deviation of those values
(see Table 2). McNair et al. also found that the inter-observer variability
in the vertical direction was the largest, suggesting it is not specific to
MR-CBCT matching but due to patient anatomy differences.
MR imaging has the ability to generate many different image con-
trasts, which could have an impact on the accuracy of MR-CBCT
matching. This study has only evaluated T2-weighted MR images and so
would not directly apply to MR images with substantially different
image contrast.
In conclusion, CBCT soft-tissue matching by experienced therapy
radiographers using an MR as the reference image appears not to be
clinically significantly different to using CT, with differences being less
Table 2
The mean ± standard deviation of the interoberserver error (standard deviation
of shifts across all observers) for the MR-CBCT and CT-CBCT matches. Data was
combined for cohorts two and three.
Match Type Axis Mean Inter-Observer Error/mm
MR-CBCT CT-CBCT
Automatic Vertical ±0.6 0.3 ±0.4 0.2
Longitudinal ±0.7 0.2 ±0.5 0.2
Lateral ±0.4 0.2 ±0.3 0.2
Soft-Tissue Vertical ±1.4 1.2 ±1.0 1.2
Longitudinal ±1.0 0.9 ±0.8 0.6
Lateral ±0.4 0.2 ±0.3 0.1
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than inter-observer variability. Relabelling the MR as a ‘CT’ in the
DICOM header does not affect the performance of the automatic re-
gistration algorithm. This suggests using a MR for soft-tissue matching
within a MR-only workflow is feasible and accurate. This will enable an
MR-only workflow to be implemented at centres where prostate fiducial
markers are not routinely used and enable the extension of MR-only
radiotherapy to other clinical sites.
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